Coni Rosati

Coni Rosati is a medical device executive with experience in product and process development, quality, clinical, regulatory and finance. Coni is currently an advisor at NeuraMedica, and has previously served as the director of R&D and CGM site manager at Bayer Diabetes Care, and as a member of the board of directors at Clarity Biosciences, Inc. Coni was also the co-founder of OxyBand Technologies Inc.

Coni has over 15 years of experience in the medical device industry. Coni has a proven track record in developing and commercializing new products and technologies. Coni has led teams through the product development process, from ideation to market launch. Coni has also managed clinical trials, submissions to the FDA, and compliance with ISO 13485, ISO 14971 and IEC 60601-1 standards.

In 2013, Coni supported Bayer's divestiture of its CGM asset. they identified a specialty investment banker and was active in the due diligence process. The CGM business was sold to Panasonic, creating Ascensia.

Coni is a passionate advocate for innovation in healthcare. Coni is a co-founder of OxyBand Technologies Inc., a company that developed a novel oxygen delivery system for patients with respiratory disorders. The company was acquired by Philips Respironics in 2008.

Coni Rosati has a BS in Applied Mechanics from UC San Diego and a certification from LinkedIn in Value-Based Pricing.